Dysglycemia as a risk factor for neurodevelopmental disorder or developmental diabetes. The risk is assessed based on measurement of a glucose control indicator in a blood sample. One particular example of a neurodevelopmental disorder is retinopathy of prematurity in an infant. One particular example of a glucose control indicator is ‘comprehensive glycated hemoglobin fraction’ or ‘comprehensive glycated albumin fraction.’ This is calculated using ‘total whole blood protein’ in the denominator. In the case of chronic hyperglycemia, there is an increased risk of proliferative retinopathy of prematurity. In the case of chronic hypoglycemia, there is an increased risk of non-proliferative retinopathy of prematurity. This ‘total whole blood protein’ technique could also be used to determine the glucose control status in other types of patients.

Provided is a method of using an aptamer for detecting a glycated hemoglobin in a whole blood, the method includes that the aptamer is provided, the aptamer includes a DNA sequence selected from the group consisting of derived sequences of SEQ ID NOs: 1, 2, 3, and 4, in which the derived sequences refer to that 3′ end and/or 5′ end of the derived sequences are modified, and the derived sequences have 90% identity to the SEQ ID NOs: 1, 2, 3, and 4. The aptamer and the whole blood are contacted. A concentration of a conjugate of the aptamer and the glycated hemoglobin is estimated. Provided also is a nanoelectronic aptasensor including the above aptamer.

A system for determining a concentration of hemoglobin A1C includes a first electrochemical test strip, the first electrochemical test strip providing for an HbA1C concentration; and a second electrochemical test strip, the second electrochemical test strip providing for the total amount of hemoglobin.

The treatment of diabetes mellitus with excellent hypoglycemic effect that suppresses lactic acidosis without substantially increasing the blood lactate concentration. A composition for treating diabetes mellitus with hypoglycemic effect that suppresses lactic acidosis without substantially increasing the blood lactate concentration, and the composition has branched-chain amino acids and salts of biguanide derivatives and derivatives of biguanide derivatives or branched-chain amino acids as the active components. The composition will be more effective when leucine, isoleucine, or valine is included as branched-chain amino acids, and metformin as the biguanide derivative.

Provided herein are thiazolidinedione analogues that are useful for treating non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), diabetes, and other metabolic inflammation-mediated disease and disorders. Further, provided herein are non-invasive methods and systems for assessing a subject's risk of having NASH. Moreover, provided herein are non-invasive methods and systems for evaluating whether a treatment of NASH is effective.

A method for measuring a proportion of sA1c (%), which includes, when a peak derived from abnormal hemoglobin D, abnormal hemoglobin S or abnormal hemoglobin C is identified, calculation of the peak area, and measurement of the proportion of sA1c (%) corrected by using the calculation results. Results of measurement are obtained, by cation exchange chromatography, of sA1c (%) with a subject who provided a blood sample containing abnormal hemoglobin D, abnormal hemoglobin S or abnormal hemoglobin C by eliminating influences by such abnormal hemoglobin.

Provided is a composition by which glycated hemoglobin can be measured even in the presence of a stronger surfactant than a conventional case. Also provided is a buffer and/or stabilizer which maintains the residual activity of an amadoriase or lowers a reduction of residual activity. The present invention provides a composition for use in measuring glycated hemoglobin containing an amadoriase having substitution of one or more amino acid residues at a position(s) corresponding to an amino acid(s) selected from the group consisting of position 262, position 257, position 249, position 253, position 337, position 340, position 232, position 129, position 132, position 133, position 44, position 256, position 231 and position 81 of an amadoriase derived from the genus Coniochaeta and represented by SEQ ID No: 1 or 3, and having residual activity even in the presence of a surfactant. The present invention also provides a composition and kit for use in measuring glycated hemoglobin, comprising a specific stabilizer and/or a buffer. The present invention can provide an enzyme and a composition for use in measuring glycated hemoglobin, excellent in storage stability even if they are exposed to a surfactant.

A method for determining analytes includes lysing the red blood cells of a whole blood sample, oxidizing the free hemoglobin in the lysed sample, and cleaving FVH from the hemoglobin A1C to form an electrochemical test solution. In one aspect, a first portion of the electrochemical test solution is reacted with fructosyl peptide oxidase and a reduced ruthenium mediator to form a first reaction product. A first electrical property of the first reaction product is measured, the measurement being indicative of hemoglobin A1C in the blood sample. In another aspect, a second portion of the electrochemical test solution is reacted with ferrocyanide to form a second reaction product. A second electrical property of the second reaction product is measured, the measurement being indicative of total hemoglobin in the blood sample. Hemoglobin A1C, total hemoglobin, and % HbA1C are determined based on the first and second electrical properties.

Provided are a measurement sample diluent that enables the measurement of the proportion of HbA1c in the total Hb molecules in a measurement sample (HbA1c (%)), with high sensitivity, high accuracy, and high correlation with HPLC without being affected by the length of time required to mix a measurement sample with the measurement sample diluent and to drop the mixture onto an immunochromatographic specimen for measuring HbA1c; and a kit containing the measurement sample diluent. The present invention relates to a measurement sample diluent for immunochromatography for quantifying the proportion of hemoglobin A1c in the total hemoglobin molecules in a measurement sample (hemoglobin A1c (%)); and the measurement sample diluent is an aqueous solution that contains a non-ionic surfactant, an anionic surfactant, and a buffer.

A method can include receiving, using one or more processors, a first record including a first data associated with a personal identification from a first database, receiving, using the one or more processors, a second record including a second data associated with a user identification from a second database, pairing, using the one or more processors, the first data and the second data based upon a shared data item contained in the first record and the second record, and displaying, using one or more processors, a report based upon the first data and the second data.